Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{182888,
        author = {Pooja Vilas Shinde and Dr. Willy Shah and Dr. Suhas Janwadkar},
        title = {Design, Synthesis, and Antimicrobial Evaluation of a Novel Imidazole–Thiadiazole–Pyrazole Hybrid Nicotinamide Bearing a Trifluoroalkyl Ether Moiety.},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {2},
        pages = {3624-3629},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=182888},
        abstract = {A novel compound, N-(4-((1H-imidazol-1-yl)methyl)-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-2-chloro-6-(3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl)nicotinamide, was designed as a potential antimicrobial agent by integrating multiple pharmacophores known for their bioactivity. The molecular architecture includes a 1,3,4-thiadiazole ring fused with imidazole and pyrazole moieties, further substituted with a trifluoromethyl ether group and anchored on a nicotinamide core. In silico ADMET analysis and docking studies predicted high bioavailability and promising binding affinities against key microbial targets such as DNA gyrase and dihydropteroate synthase. Preliminary antimicrobial assays demonstrated significant inhibitory activity against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans. This work showcases the compound’s potential as a broad-spectrum antimicrobial agent.},
        keywords = {5-aminno-1,3,4-thiadiazol-thiol, Imidazole, Antimicrobial, Anti-inflammatory activity, Pyrazole, Nicotinamide , ADMET , Molecular Docking.},
        month = {July},
        }